Adagrasib price

Adagrasib (Adagrasib) is a revolutionary small molecule targeted drug specifically used to treat non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. KRAS G12CMutation is a common cancer driver gene mutation that occurs frequently in lung cancer patients.

Adagrasib is not currently available in the country, so patients cannot purchase it domestically and can only purchase adagrasib through overseas channels. Abroad, there is only the original American drug adagrasib, and the price is very high, as high as about 190,000 yuan.

The development of this drug fills a long-standing gap in the field of KRAS gene mutation treatment, because KRAS has long been considered one of the cancer genes that is difficult to target. The uniqueness of adagrasib is that it can specifically act on the KRAS G12C mutation, blocking the abnormal cell signaling caused by this mutation, thereby inhibiting the growth and division of cancer cells.

By binding to KRAS G12C mutated protein, adagrasib can interfere with the survival mechanism of cancer cells, providing patients with a new treatment option. Clinical trials have shown that adagrasib has significant efficacy in patients with KRAS G12C mutations who have received other treatments and developed resistance.

Despite encouraging results with adagrasib in the treatment of KRAS G12Cmutated non-small cell lung cancer, further research is needed to understand its long-term efficacy and potential side effects. This emerging therapeutic agent represents a positive breakthrough in cancer treatment and provides more hope and opportunities for patients with KRAS mutation-related cancers. In the future, as scientific research continues to deepen, adagrasib is expected to play an increasingly important role in the treatment of lung cancer.